Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00474253
Status:
COMPLETED
Last Update Posted:
2019-04-11
First Post:
2007-05-15
Brief Title:
Comparison of Recovery From Rocuronium 12 mgkg Followed by Sugammadex Org 25969 16 mgkg at 3 Minutes With Recovery From Succinylcholine 10 mgkg 194303P05946MK-8616-026
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multicenter Randomized Parallel Group Comparative Active-Controlled Safety-Assessor Blinded Phase IIIa Trial in Adult Subjects Comparing Recovery From 12 mgKg-1 Rocuronium Followed by 16 mgKg-1 Org 25969 at 3 Minutes With Recovery From 10 mgKg-1 Succinylcholine
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the trial is to demonstrate a faster recovery from neuromuscular block induced by 12 mgkg rocuronium after reversal at 3 minutes by 160 mgkg of sugammadex compared with recovery after a neuromuscular block induced by 10 mgkg succinylcholine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-8616-026 | OTHER | Merck Protocol Number | None |
| 194303 | OTHER | None | None |
| P05946 | OTHER | None | None |